Recently, Han et al. have reported that T-cell receptor diversity in peripheral blood PD1+ CD8+ T cells could predict clinical outcomes in patients with non-small cell lung cancer, suggesting that levels of CD8+ T cells together with T cell exhaustion markers may serve as useful clinical biomarkers in cancer [40]. This evidence concerns the gene CD8A and cancer.